Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Non-Current AssetsPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury Shares
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

BioCorRx (BICX) Accumulated Expenses (2016 - 2025)

Historic Accumulated Expenses for BioCorRx (BICX) over the last 9 years, with Q3 2025 value amounting to $317577.0.

  • BioCorRx's Accumulated Expenses changed N/A to $317577.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $317577.0, marking a year-over-year change of. This contributed to the annual value of $983.0 for FY2021, which is 44916.2% up from last year.
  • BioCorRx's Accumulated Expenses amounted to $317577.0 in Q3 2025.
  • BioCorRx's 5-year Accumulated Expenses high stood at $317577.0 for Q3 2025, and its period low was $299.0 during Q2 2021.
  • Its 3-year average for Accumulated Expenses is $78279.0, with a median of $1472.0 in 2022.
  • Data for BioCorRx's Accumulated Expenses shows a peak YoY increase of 73055.56% (in 2021) and a maximum YoY decrease of 44916.2% (in 2021) over the last 5 years.
  • BioCorRx's Accumulated Expenses (Quarter) stood at $983.0 in 2021, then surged by 68.06% to $1652.0 in 2022, then soared by 19123.79% to $317577.0 in 2025.
  • Its Accumulated Expenses stands at $317577.0 for Q3 2025, versus $147871.0 for Q2 2025 and $1652.0 for Q2 2022.